L-glutamine

Overview

L-glutamine is the biologically active L-enantiomer of glutamine, a proteinogenic amino acid and one of the most abundant free Amino Acids in human tissues and circulation. It serves as a key nitrogen donor in intermediary metabolism and supports multiple cellular processes, including amino acid biosynthesis, nucleotide synthesis, redox balance, and energy metabolism. Because of these roles, L-glutamine is often described as a conditionally essential amino acid, particularly during physiological stress, illness, or rapid growth.

In biomedical research, L-glutamine is frequently studied in relation to mitochondrial function, immune and intestinal metabolism, and amino-acid–dependent signaling. Recent work has also linked glutamine availability to disease-relevant metabolic rewiring, including cancer metastasis, muscle and joint metabolism, and neuro-metabolic changes. In these contexts, glutamine intersects with pathways involving mitochondrion function, glutamic acid, tryptophan, and broader amino acid networks, and it may be influenced by interventions such as semaglutide, fluoxetine, butyric acid, or engineered microbial therapies.

Recent Publications Focus

Below is a summary of the newest research publications targeting L-glutamine (sorted by publication date).

Recent studies have continued to position L-glutamine as a central metabolic node in cancer biology and therapeutic support. In oncology-focused work, glutamine metabolism was highlighted as a vulnerability in myeloma and leukemia, and broader conference coverage emphasized the growing interest in metabolic dependencies as actionable targets in precision cancer care. Another recent analysis linked aging-driven metastatic progression in Kras-mutant lung adenocarcinoma to an acquired dependence on glutamine, suggesting that host aging can reshape tumor metabolism in ways that favor distant spread.

Several studies examined how glutamine metabolism contributes to the tumor microenvironment and invasion. In squamous cell carcinoma, oxidative stress induced senescent macrophages with distinct secretory phenotypes, and integrated metabolomic and transcriptomic analyses identified the glutamine-glutamate pathway as a central hub. Upregulation of glutaminase 2 and increased glutaminolysis were associated with IL-1β expression, and the resulting IL-1β/IL-1R2/NF-κB signaling axis promoted tumor invasion; targeting this glutamine metabolism-regulated pathway suppressed invasion. These findings connect glutamine metabolism to senescence-associated secretory programs and proinvasive inflammatory signaling.

Glutamine also appeared in studies of supportive care and host metabolism. A prospective exploratory study evaluated continuous oral supplementation with β-hydroxy-β-methylbutyrate, arginine, and glutamine during carbon-ion radiotherapy for head and neck cancer, focusing on feasibility in the setting of acute mucositis and dermatitis. In a separate mechanistic study of osteoarthritis, semaglutide was reported to act on muscle mitochondria to regulate glutamine metabolism, increasing circulating glutamine and reducing muscle glutaminase activity; mitochondria from semaglutide-stimulated C2C12 cells alleviated pain, cartilage damage, and chondrocyte inflammation, supporting a muscle-cartilage axis involving glutamine.

Outside oncology and musculoskeletal disease, L-glutamine was also discussed in the context of engineered probiotics for hepatic encephalopathy, where a bacterial cocktail was designed to neutralize toxic ammonia and L-glutamine while replenishing essential Amino Acids. In addition, a nanopore engineering study used glutamine recognition by a substrate-binding domain protein as a model system to improve single-molecule monitoring of conformational changes, showing that rational mutagenesis of ClyA nanopores could amplify the signal associated with glutamine binding.

Method PMIDs

[PMID 42212725]

Result PMIDs

[PMID 41796893]
[PMID 41956049]
[PMID 42104939]
[PMID 42314122]
[PMID 42321971]

Target PMIDs

[PMID 42013364]
[PMID 42269583]
[PMID 42305583]
[PMID 42328825]
[PMID 42333921]
[PMID 42379751]
[PMID 42388021]